Relationship between vitamin D deficiency and development of neurodegenerative disorders. Systematic Review
DOI:
https://doi.org/10.59471/ijhsc2023154Keywords:
Vitamin D, Vitamin D and Alzheimer’s Disease, Vitamin D and Parkinson’s Disease, Vitamin D and Multiple Sclerosis, Preventive and Vitamin DAbstract
Introduction: vitamin D achieved a leading role in areas of biomedical research because it is produced industrially to be used in food and dietary supplements. Its deficit is prevalent in many countries regardless of geographic location or time of year. Beyond its role in calcium and skeletal metabolism, its insufficiency is identified in the pathogenesis of multiple diseases such as Alzheimer’s and Parkinson’s. Analyzed studies show that low levels of vitamin D in plasma increase the risk of dementia, motor-cognitive impairment and contribute to decreased memory.
Objectives: to determine the relationship between vitamin D deficiency and the development of neurodegenerative diseases such as: Multiple Sclerosis, Parkinson’s and Alzheimer’s, as well as the possible therapeutic effects of its supplementation to understand its relevance and inform treatment strategies in patients with these pathologies.
Method: a systematic review of the literature was carried out, collecting selected articles on scientific research platforms: PubMed, Google Schoolar, SciELO, MedLine Plus, Elservier.es, Neurología.com, Isanidad.com in order to retrospectively analyze the relationship between vitamin D deficiency and the establishment of neurodegenerative diseases in certain documented study populations with the purpose of encouraging new research that analyzes possible therapeutic effects of Vitamin D supplementation in the course of neurodegenerative pathologies
References
DeLuca HF. Overview of general physiologic features and functions of vitamin D. The American Journal of Clinical Nutrition. 1 de diciembre de 2004;80(6):1689S-1696S.
Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium Absorption Varies within the Reference Range for Serum 25-Hydroxyvitamin D. Journal of the American College of Nutrition. abril de 2003;22(2):142-6.
Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for Cancer Prevention: Global Perspective. Annals of Epidemiology. julio de 2009;19(7):468-83.
Holick MF. Vitamin D Deficiency. N Engl J Med. 19 de julio de 2007;357(3):266-81.
Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain. Journal of Chemical Neuroanatomy. enero de 2005;29(1):21-30.
Balion C, Griffith LE, Strifler L, Henderson M, Patterson C, Heckman G, et al. Vitamin D, cognition, and dementia: A systematic review and meta-analysis. Neurology. 25 de septiembre de 2012;79(13):1397-405.
Annweiler C, Llewellyn DJ, Beauchet O. Low Serum Vitamin D Concentrations in Alzheimer’s Disease: A Systematic Review and Meta-Analysis. JAD. 10 de enero de 2013;33(3):659-74.
Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-Hydroxyvitamin D Levels and Risk of Multiple Sclerosis. JAMA. 20 de diciembre de 2006;296(23):2832.
Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PHM, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2 de septiembre de 2014;83(10):920-8.
Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25‐hydroxyvitamin D and risk of Alzheimer’s disease and vascular dementia. Alzheimer’s & Dementia. mayo de 2014;10(3):296- 302.
Peterson AL, Mancini M, Horak FB. The relationship between balance control and vitamin D in Parkinson’s disease-a pilot study: Balance and Vitamin D in PD. Mov Disord. julio de 2013;28(8):1133-7.
Peterson AL, Murchison C, Zabetian C, Leverenz JB, Watson GS, Montine T, et al. Memory, Mood, and Vitamin D in Persons with Parkinson’s Disease. Journal of Parkinson’s Disease. 2013;3(4):547-55.
Landfield PW, Thibault O, Mazzanti ML, Porter NM, Kerr DS. Mechanisms of neuronal death in brain aging and alzheimer’s disease: Role of endocrine- mediated calcium dyshomeostasis. J Neurobiol. noviembre de 1992;23(9):1247-60.
Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D Hormone Confers Neuroprotection in Parallel with Downregulation of L-Type Calcium Channel Expression in Hippocampal Neurons. J Neurosci. 1 de enero de 2001;21(1):98-108.
Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, et al. 1α,25-dihydroxyvitamin D3 Interacts with Curcuminoids to Stimulate Amyloid-β Clearance by Macrophages of Alzheimer’s Disease Patients. JAD. 1 de julio de 2009;17(3):703-17.
Mizwicki MT, Menegaz D, Zhang J, Barrientos-Durán A, Tse S, Cashman JR, et al. Genomic and Nongenomic Signaling Induced by 1α,25(OH)2- Vitamin D3 Promotes the Recovery of Amyloid-β Phagocytosis by Alzheimer’s Disease Macrophages. JAD. 2 de marzo de 2012;29(1):51-62.
Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 1 de mayo de 2009;132(5):1146-60.
Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, et al. Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency: A Meta-analysis of Randomized Controlled Trials. Arch Intern Med. 23 de marzo de 2009;169(6):551.
Kesby JP, Eyles DW, Burne THJ, McGrath JJ. The effects of vitamin D on brain development and adult brain function. Molecular and Cellular Endocrinology. diciembre de 2011;347(1-2):121-7.
Pascual ALC. LA VITAMINA D Y SUS EFECTOS “NO CLÁSICOS”. Rev Esp Salud Pública. 2012;86:7.
Leussink VI. Aspekte der Ernährung zur Prävention und Therapie chronisch neurologischer Erkrankungen. Nervenarzt. agosto de 2019;90(8):843- 57.
Landel V, Annweiler C, Millet P, Morello M, Féron F. Vitamin D, Cognition and Alzheimer’s Disease: The Therapeutic Benefit is in the D- Tails. Wion D, editor. JAD. 13 de julio de 2016;53(2):419-44.
Aspell N, Lawlor B, O’Sullivan M. Is there a role for vitamin D in supporting cognitive function as we age? Proc Nutr Soc. mayo de 2018;77(2):124-34.
Shen L, Ji HF. Vitamin D deficiency is associated with increased risk of Alzheimer’s disease and dementia: evidence from meta-analysis. Nutr J. 1 de agosto de 2015;14:76.
Di Somma C, Scarano E, Barrea L, Zhukouskaya V, Savastano S, Mele C, et al. Vitamin D and Neurological Diseases: An Endocrine View. IJMS. 21 de noviembre de 2017;18(11):2482.
Reichrath J, Lehmann B, Carlberg C, Varani J, Zouboulis C. Vitamins as Hormones. Horm Metab Res. febrero de 2007;39(2):71-84.
Holick MF. Vitamin D Deficiency. N Engl J Med. 19 de julio de 2007;357(3):266-81.
Moretti R, Morelli ME, Caruso P. Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact. IJMS. 31 de julio de 2018;19(8):2245.
Taghizadeh M, Talaei SA, Djazayeri A, Salami M. Vitamin D supplementation restores suppressed synaptic plasticity in Alzheimer’s disease. Nutritional Neuroscience. julio de 2014;17(4):172-7.
Bivona G, Gambino CM, Iacolino G, Ciaccio M. Vitamin D and the nervous system. Neurological Research. 2 de septiembre de 2019;41(9):827-35.
DeLuca GC, Kimball SM, Kolasinski J, Ramagopalan SV, Ebers GC. Review: The role of vitamin D in nervous system health and disease: Vitamin D and the brain. Neuropathol Appl Neurobiol. agosto de 2013;39(5):458-84.
Mpandzou G, Aït Ben Haddou E, Regragui W, Benomar A, Yahyaoui M. Vitamin D deficiency and its role in neurological conditions: A review. Revue Neurologique. febrero de 2016;172(2):109-22.
Dursun E, Gezen-Ak D. Vitamin D basis of Alzheimer’s disease: from genetics to biomarkers. Hormones. marzo de 2019;18(1):7-15.
Annweiler C. Vitamin D in dementia prevention: Vitamin D and dementia. Ann NY Acad Sci. marzo de 2016;1367(1):57-63.
Zhou Z, Zhou R, Zhang Z, Li K. The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson’s Disease: A Systematic Review and Meta-Analysis. Med Sci Monit. 23 de enero de 2019;25:666-74.
Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The Incidence of Parkinson’s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2016;46(4):292- 300.
Romano MF, Nissen MD, Parquet DCA. ENFERMEDAD DE ALZHEIMER. 2007; Enfermedad de Alzheimer. Guía de práctica clínica [Internet]. [citado 14 de diciembre de 2022]. Disponible en: https://www.elsevier.es/es-revista-neurologia-argentina-301-pdf-S185300281170026X
(1) (PDF) ENFERMEDADES DEGENERATIVAS DEL SISTEMA NERVIOSO CENTRAL [Internet]. [citado 14 de diciembre de 2022]. Disponible en: https://www.researchgate.net/publication/341616836_ENFERMEDADES_DEGENERATIVAS_DEL_SISTEMA_NERVIOSO_CENTRAL
Cardoso B, Cominetti, Cozzolino. Importance and management of micronutrient deficiencies in patients with Alzheimer’s disease. CIA. mayo de 2013;531.
Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PHM, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2 de septiembre de 2014;83(10):920-8.
Martín Sánchez FJ, Ramírez Díaz SP, Gil Gregorio P. Las enfermedades neurodegenerativas vistas desde la geriatría. Demencias: concepto, clasificación, valoración clinicodiagnóstica y tratamiento. Medicine - Programa de Formación Médica Continuada Acreditado. enero de 2003;8(108):5786-94.
Annweiler C, Allali G, Allain P, Bridenbaugh S, Schott AM, Kressig RW, et al. Vitamin D and cognitive performance in adults: a systematic review. European Journal of Neurology. octubre de 2009;16(10):1083-9.
White JH. Vitamin D Signaling, Infectious Diseases, and Regulation of Innate Immunity. Infect Immun. septiembre de 2008;76(9):3837-43.
Kampman MT, Brustad M. Vitamin D: Candidate for the Environmental Effect in Multiple Sclerosis – Observations from Norway. Neuroepidemiology. 2008;30(3):140-6.
Uría D, Pérez M, Tola-Arribas M. Epidemiología de la esclerosis múltiple. En 2021. p. 321-40.
Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. Journal of Neuroimmunology. enero de 2003;134(1-2):128-32.
Kampman MT, Steffensen LH. The role of vitamin D in multiple sclerosis. Journal of Photochemistry and Photobiology B: Biology. noviembre de 2010;101(2):137-41.
Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. Journal of Neuroimmunology. febrero de 2008;194(1-2):7-17.
Orton SM, Ramagopalan SV, Para AE, Lincoln MR, Handunnetthi L, Chao MJ, et al. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. Journal of the Neurological Sciences. junio de 2011;305(1-2):116- 20.
Kampman MT, Brustad M. Vitamin D: A Candidate for the Environmental Effect in Multiple Sclerosis – Observations from Norway. Neuroepidemiology. 2008;30(3):140-6.
Simpson S, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS. Ann Neurol. 6 de abril de 2010;n/a- n/a.
The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. julio de 2009;41(7):824-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Delfina Plaini, María de los Ángeles Baña (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
How to Cite
